Literature DB >> 33131242

Transforming the major autoantibody site on ADAMTS13: spacer domain variants retaining von Willebrand factor cleavage activity.

Marie Scully1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33131242      PMCID： PMC7604561          DOI： 10.3324/haematol.2020.262154

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Vickie McDonald; Jamie Cavenagh; Beverley J Hunt; Ian Longair; Hannah Cohen; Samuel J Machin
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

3.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

4.  Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Yusuke Yamaguchi; Takanori Moriki; Atsuko Igari; Terumichi Nakagawa; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata
Journal:  Thromb Res       Date:  2011-04-14       Impact factor: 3.944

5.  Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.

Authors:  B M Luken; P H P Kaijen; E A M Turenhout; J A Kremer Hovinga; J A van Mourik; R Fijnheer; J Voorberg
Journal:  J Thromb Haemost       Date:  2006-08-08       Impact factor: 5.824

Review 6.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.

Authors:  M Furlan; B Lämmle
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

7.  Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.

Authors:  John-Paul Westwood; Mari Thomas; Ferras Alwan; Vickie McDonald; Sylvia Benjamin; William A Lester; Gillian C Lowe; Tina Dutt; Quentin A Hill; Marie Scully
Journal:  Blood Adv       Date:  2017-06-26

8.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

9.  An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.

Authors:  Wouter Pos; James T B Crawley; Rob Fijnheer; Jan Voorberg; David A Lane; Brenda M Luken
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

10.  Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Nuno A G Graça; Bogac Ercig; Leydi Carolina Velásquez Pereira; Kadri Kangro; Paul Kaijen; Gerry A F Nicolaes; Agnès Veyradier; Paul Coppo; Karen Vanhoorelbeke; Andres Männik; Jan Voorberg
Journal:  Haematologica       Date:  2020-11-01       Impact factor: 9.941
View more
  1 in total

Review 1.  TTP: From empiricism for an enigmatic disease to targeted molecular therapies.

Authors:  Nuno A G Graça; Bérangère S Joly; Jan Voorberg; Karen Vanhoorelbeke; Nicolas Béranger; Agnès Veyradier; Paul Coppo
Journal:  Br J Haematol       Date:  2022-02-10       Impact factor: 8.615
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.